ROSSARI BIOTECH LIMITED
ROSSARI · General/Diversified · NSE
₹519
Current Market Price
Fair Value (DCF)
₹515
Discount to FV
-0.8%
Updated just now
YieldIQ Score
53/100
Piotroski F-Score
4/9
Economic Moat
Moderate
Confidence
31%
ROE
11.5%
Debt/Equity
0.18
WACC
11.1%
Market Cap
₹2,874 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
19.2%
Return on capital employed
EV / EBITDA
11.2×
Enterprise multiple
Debt / EBITDA
1.5×
Leverage vs earnings
Interest Coverage
11.4×
EBIT covers interest
Current Ratio
1.94×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
13.2%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹518.85
Bear case
Discount -73.1%
Base case
Discount -0.8%
Bull case
Discount +22.0%
Ratio Trends
ROSSARI · last 5 annual periods
ROE
11.5%
ROCE
19.2%
Operating Margin
—
Debt / Equity
0.18×
PE
113.9×
EV / EBITDA
14.3×
Historical Financials
ROSSARI · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1483 Cr | ₹1651 Cr | ₹1825 Cr | ₹2080 Cr | ₹2396 Cr | +12.7% |
| EBITDA | ₹197 Cr | ₹229 Cr | ₹257 Cr | ₹270 Cr | ₹310 Cr | +12.0% |
| EBIT | ₹147 Cr | ₹166 Cr | ₹197 Cr | — | — | +7.5% |
| PAT | ₹97.7 Cr | ₹107 Cr | ₹131 Cr | ₹136 Cr | ₹149 Cr | +11.2% |
| EPS (diluted) | ₹17.70 | ₹19.38 | ₹23.62 | — | — | +7.5% |
| CFO | ₹29.4 Cr | ₹152 Cr | ₹43.3 Cr | ₹137 Cr | ₹65.1 Cr | +22.0% |
| CapEx | ₹-38.2 Cr | ₹-32.9 Cr | ₹-131 Cr | ₹-159 Cr | ₹-265 Cr | — |
| FCF | ₹-8.9 Cr | ₹119 Cr | ₹-88.0 Cr | ₹-21.1 Cr | ₹-200 Cr | — |
| Total Assets | ₹1257 Cr | ₹1368 Cr | ₹1572 Cr | ₹1896 Cr | ₹2289 Cr | +16.2% |
| Total Debt | ₹8.4 Cr | ₹73.9 Cr | ₹119 Cr | ₹218 Cr | ₹436 Cr | +168.2% |
| Shareholders' Equity | ₹805 Cr | ₹915 Cr | ₹1048 Cr | ₹1185 Cr | ₹1333 Cr | +13.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ROSSARI vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 POLYPLEX POLYPLEX | — | — | Pending | 3.4% | — |
JUBLCPL JUBILANT AGRI N CON PRO L | -6.2% | 73 | Data Limited | 27.8% | — |
KIRIINDUS KIRIINDUS | — | — | Pending | 8.2% | — |
 NOCIL NOCIL | — | — | Pending | 3.1% | — |
FCL FCL | — | — | Pending | 12.3% | 20.6× |
Click a ticker to view its fair-value analysis.
Dividend History
5 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹2.50/sh
Last payout
2025-06-20
₹0.50
Peak payout
₹0.50
Trailing yield
0.10%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. ROSSARI BIOTECH LIMITED (ROSSARI.NS) trades at 518.85 vs a model fair value of 514.78, a gap of -0.8%. Piotroski F-score: 4/9. Moat label...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ROSSARI →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ROSSARI →
Compare
Head-to-head with peers
Compare ROSSARI side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ROSSARINow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.